ASTRAZENECA PLC vs REGENERON PHARMACEUTICALS, INC., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Regeneron turns each dollar of assets into more profit than AstraZeneca, 10.8% on assets to 9.0%, even though AstraZeneca earns the higher return on equity, 21% to 14%. The reason is structural: AstraZeneca leans on a 0.94 current ratio and a fuller balance sheet to lift equity returns, while Regeneron sits on a 3.57 current ratio and almost no debt, so its lower leverage drags equity returns down even as the underlying assets work harder. Regeneron also keeps more of each sales dollar, a 30% net margin to AstraZeneca's 17%, and throws off a 6.2% free-cash yield to 4.3%. The market reads them inversely to the leverage, paying 27 times earnings for AstraZeneca and 15 for Regeneron. The cleaner balance sheet earns less on equity by choice, not by weakness.
Comparison updated 2026-06-15.
| Metric | AZN | REGN |
|---|---|---|
| Price | $171.60 | $664.56 |
| Market cap | $266.0B | $71.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +21.0% | +8.8% |
| P/E | 26.0 | 16.2 |
| P/B | 5.46 | 2.28 |
| P/S | 4.53 | 4.80 |
| EV/EBITDA | 18.9 | 18.8 |
| Revenue growth | +12.1% | +6.5% |
| Gross margin | 81.9% | — |
| Operating margin | 23.4% | 17.8% |
| Net margin | 17.4% | 29.6% |
| Return on equity | 21.0% | 14.1% |
| Return on assets | 9.0% | 10.8% |
| Return on invested capital | 23.3% | 9.5% |
| FCF yield | 4.4% | 5.8% |
| Debt / equity | 0.00 | 0.06 |
| Current ratio | 0.94 | 3.57 |
| Altman Z (solvency) | 3.47 | 6.60 |
| Piotroski F (quality) | 8 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.